Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala discussed the company’s strategic partnership with WuXi XDC, calling it a milestone that validates Akari’s PH1 spliceosome‑modulating payload platform.
The interview said the collaboration goes beyond a typical CDMO role, is expected to reduce execution risk and accelerate an IND filing for AKTX-101 to late 2026, and positions Akari within the evolving ADC market.
AI-generated analysis. Not financial advice.
Positive
- Strategic partnership with WuXi XDC provides development and manufacturing support
- Platform validation for PH1 spliceosome‑modulating payloads via partnership endorsement
- IND timeline accelerated with AKTX-101 anticipated to file in late 2026
- Reduced execution risk and clearer path toward first‑in‑human studies
Negative
- None.
News Market Reaction – AKTX
On the day this news was published, AKTX gained 1.03%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $48K to the company's valuation, bringing the market cap to $4.68M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
Momentum scanner data flagged AKTX direction as down while only one peer, NRXS, appeared with a 5.07% upside move and no news. Other biotech peers in the reference list show mixed-to-negative daily changes, indicating stock-specific dynamics rather than a coordinated sector reaction to this partnership commentary.
Previous Partnership Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | Strategic partnership | Positive | -20.8% | Announced WuXi XDC partnership to speed PH1 ADC platform and AKTX-101 IND. |
The prior WuXi XDC partnership announcement, a positive strategic milestone, was followed by a sharply negative -20.81% move, signaling a tendency for investors to sell into partnership news.
Over the past months, Akari has focused on building its ADC platform and advancing lead program AKTX-101 toward an IND by late 2026. The key prior event matching today’s theme was the Apr 06, 2026 strategic partnership announcement with WuXi XDC, intended to accelerate development of the PH1 ADC payload and AKTX-101. Despite its positive strategic framing, the stock fell 20.81% over the next 24 hours, showing a sharp divergence between news tone and price reaction.
Historical Comparison
In the past 6 months, Akari reported 1 partnership-related event. That WuXi XDC deal update saw a -20.81% move, so any modest reaction to this follow-on interview would be smaller than the prior swing.
Both the prior release and this interview center on the WuXi XDC collaboration and its role in validating the PH1 ADC payload platform and moving lead candidate AKTX-101 toward an IND by late 2026 and first-in-human studies.
Regulatory & Risk Context
The company has an active, effective S-3 shelf registration filed on 2025-07-29, with at least two takedowns via 424B5 prospectuses in late 2025. This structure provides pre-cleared capacity for future securities offerings, which can facilitate capital raises but also represents a potential source of dilution for existing shareholders.
Market Pulse Summary
This announcement reinforces Akari’s strategic partnership with WuXi XDC and its aim to accelerate AKTX-101 toward an IND by late 2026 and first-in-human studies. It echoes the prior Apr 06, 2026 deal release, which drew a -20.81% move despite positive messaging, highlighting a gap between narrative and market response. Investors may focus on execution milestones, IND-enabling progress, capital-raising via the active S-3 shelf, and how Akari differentiates its PH1 ADC platform within a crowded ADC landscape.
Key Terms
antibody drug conjugates medical
ADCs medical
RNA splicing medical
PH1 spliceosome-modulating payload medical
CDMO technical
IND filing regulatory
first-in-human clinical studies medical
AI-generated analysis. Not financial advice.
CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration
Company highlights accelerated IND timeline for AKTX-101 and positioning within the rapidly evolving ADC landscape
Watch the “What This Means” video here
TAMPA and LONDON, April 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, today announced that Abizer Gaslightwala, Director, President and CEO of Akari Therapeutics, participated in a Virtual Investor “What This Means” interview focused on the Company’s recently announced strategic partnership with WuXi XDC.
As part of the segment, Mr. Gaslightwala discussed how the strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, represents an important milestone for Akari and further validates its novel PH1 spliceosome-modulating payload platform. The discussion highlighted how the relationship extends beyond a traditional CDMO engagement, supporting Akari’s ability to efficiently advance its ADC programs and strengthen execution across development.
Mr. Gaslightwala also addressed how the partnership is expected to accelerate the development timeline of Akari’s lead program, AKTX-101, with an anticipated IND filing in late 2026. The segment explored how the collaboration enhances Akari’s development capabilities, reduces execution risk, and establishes a clearer path toward first-in-human clinical studies.
In addition, the discussion provided perspective on the broader ADC market, including increasing deal activity and recent large-scale transactions, and how Akari’s strategic partnership positions the Company within this evolving landscape. The segment also touched on Akari’s long-term development strategy and potential partnering opportunities as it continues to advance its platform.
The Virtual Investor “What This Means” segment featuring Akari Therapeutics is now available here.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
